The Board of Directors has in accordance with its guidelines and instructions assigned to the Company’s CEO, Tomas Blomquist, to manage the Company’s affairs. The CEO, and the Executive Management under the supervision of the CEO, are responsible for the Group’s day-to-day business and management. The CEO regularly reports to the Board of Directors on how the Company’s business performs, financial results, and other important issues.
Tomas Blomquist is CEO & President at Biotage as of November 6, 2019. Mr. Blomquist is born in 1970 and has more than 25 years of international experience within the healthcare industry, particularly in the Diagnostics & Medtech area. He has held executive positions at Abbott, Roche, Johnson & Johnson and Analyticon Biotechnologies. Mr. Blomquist has built sustainable high performing organizations and profitable growth companies through direct and indirect sales channels in more than 100 countries. He has extensive expertise in corporate strategy, people development, business model innovation, Internationalization, organizational design and commercialization. Mr. Blomquist is a former middle-distance runner, lives in Stockholm and is passionate to creating value and results to personnel, customers, environment, society and shareholders.
Andrew Kellett is the CFO at Biotage as of September 25th 2023. Andrew has a strong track record in the financial and operational leadership of international science and technology growth companies. Most recently, Andrew was the CFO of Technetix Group, an international technology business. His previous roles have included CFO of Genetix PLC, a publicly listed business, here he played a key role in the growth, transformation, and successful sale of the company to the Danaher Corporation. He also held CFO positions at Cmed Group, an international CRO and the Global Controller of the Clinical Trials and Pharmaceutical Development business of Quest Diagnostics, a fortune 500 company. Andrew is a Chartered Accountant having qualified with Coopers and Lybrand.